POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery
Bibliographic record
Abstract
BACKGROUND: Cardiac surgery with cardiopulmonary bypass invariably induces renal stress and risk of irreversible kidney function loss, with no approved drug treatments. RMC-035, a recombinant human alpha-1-microglobulin with potent heme-binding and antioxidant capacity, has shown promising long-term kidney-protective effects in a phase 2a trial of patients undergoing cardiac surgery. The primary objective of this phase 2b dose-optimisation trial is to demonstrate that RMC-035 (pooled dose groups) is superior to placebo in preserving renal function at 90 days after surgery. METHODS: This randomised, blinded, placebo-controlled, multicentre study evaluates the efficacy and safety of RMC-035 among approximately 161 high-risk patients undergoing cardiac surgery who are randomised into one of three treatment groups in a 2:2:3 ratio: RMC-035 (30 mg or 60 mg) or placebo. The study drug is administered via three intravenous infusions, with the first dose given intraoperatively, followed by additional doses at 6 and 24 h, respectively. The primary endpoint is the change in estimated glomerular filtration rate (eGFR) from baseline (pre-surgery) to Day 90. Important secondary endpoints include the incidence of major adverse kidney events at Day 90 and short-term outcomes reflecting changes in renal filtration markers up to Day 7. Safety assessments encompass adverse events, vital signs, electrocardiograms and routine safety laboratory tests. Additional evaluations include pharmacokinetics, anti-drug antibodies and immunological biomarkers. DISCUSSION: This multicentre, multinational phase 2b trial, will assess the change in eGFR within 90 days of the first dose, providing additional evidence of the long-term kidney-protective potential of RMC-035 in patients undergoing cardiac surgery at high risk for kidney injury. Trial outcomes will inform the preferred dose, dosing regimen, and benefit-risk profile related to cardiac surgery for a future pivotal phase 3 trial. TRIAL REGISTRATION: The trial was registered June 20, 2024, at Clinicaltrials.gov (NCT06475274 https://clinicaltrials.gov/study/NCT06475274 ). The trial including the participating EU countries is also registered with the EUCT number 2024-510658-28 under https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-510658-28-00 . The first patient was enrolled August 26, 2024.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.020 | 0.022 |
| Meta-epidemiology (narrow) | 0.005 | 0.003 |
| Meta-epidemiology (broad) | 0.008 | 0.004 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.004 | 0.003 |
| Scholarly communication | 0.003 | 0.003 |
| Open science | 0.004 | 0.002 |
| Research integrity | 0.008 | 0.010 |
| Insufficient payload (model declined to judge) | 0.165 | 0.038 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".